US6700024010 - Common Stock
The FDA's experts voted in favor of annual boosters on Thursday.
These beaten-down stocks could be poised for major rebounds.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
If you want to invest in volatile stocks, a certain strategy can minimize your overall risk.
Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze.
At such a beaten-down valuation, is the upside for Novavax just too significant to ignore?
Can Novavax still win over the long term?
All three stocks have promising therapies that could drive revenue in the coming years.
Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock.
Any bit of good news could send these stocks soaring.
The stock has gone on a wild ride over the past few years.
Novavax stock would likely have fallen in 2022 even in a bull market.
Novavax stock sank 92% last year.
The COVID-19 public health emergency, in place since January 2020, has again been renewed, HHS Secretary Xavier Becerra said.
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
These innovative growth stocks have the tailwinds necessary to deliver triple-digit returns for their shareholders by mid-2024.
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries.
Ocugen is hoping its Indian-made inactivated Covid-19 shot can provide a low-cost boost for those previously given MRNA-based vaccines.
Novavax (NVAX) said on Monday its Chief Executive Officer Stanley Erck will retire from his position on January 23, and will be succeeded by John Jacobs. The company said Erck, who...
Could the biotech be the ultimate contrarian buy of 2023?
Sales of Paxlovid and Comirnaty are expected to continue declining this year and next.
Triple-digit returns could be just a click away from the buy button.
These biotechs are far from having achieved their full potential.
Novavax (NVAX) announced Friday the initiation of a Phase 2 trial to evaluate its COVID-19-flu combination ((CIC)) vaccine in Australia and New Zealand. Read the full story here.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
GAITHERSBURG, Md., Dec. 28, 2022 /PRNewswire/ -- On December 20, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company (the 'Company' or 'No...